You are currently on the new version of our website. Access the old version .

516 Results Found

  • Review
  • Open Access
155 Citations
14,237 Views
12 Pages

Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System

  • Mona O. Mohsen,
  • Ariane C. Gomes,
  • Monique Vogel and
  • Martin F. Bachmann

Virus-like particles (VLPs) derived from viral nucleocapsids are an important class of nanoparticles. The structure, uniformity, stability, and function of these VLPs have attracted scientists in utilizing them as a unique tool in various application...

  • Article
  • Open Access
4 Citations
2,867 Views
17 Pages

27 September 2023

Virus-like particles (VLPs) have been proposed as an attractive tool in SARS-CoV-2 vaccine development, both as (1) a vaccine candidate with high immunogenicity and low reactogenicity and (2) a substitute for live virus in functional and neutralizati...

  • Article
  • Open Access
6 Citations
4,505 Views
16 Pages

Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell Pool

  • Sitthiphol Puarattana-aroonkorn,
  • Kannan Tharakaraman,
  • Disapan Suriyawipada,
  • Mathuros Ruchirawat,
  • Mayuree Fuangthong,
  • Ram Sasisekharan and
  • Charlermchai Artpradit

At times of pandemics, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the situation demands rapid development and production timelines of safe and effective vaccines for delivering life-saving medications quickly...

  • Article
  • Open Access
3 Citations
4,962 Views
10 Pages

SARS-CoV-2 Virus-like Particles (VLPs) Specifically Detect Humoral Immune Reactions in an ELISA-Based Platform

  • Stefan Hirschberg,
  • Hannes Bauer,
  • Julian Kamhieh-Milz,
  • Frauke Ringel,
  • Christoph Harms,
  • Omar Kamal Eddin,
  • Axel Pruß,
  • Katja Hanack and
  • Kai Schulze-Forster

12 December 2022

A key in controlling the SARS-CoV-2 pandemic is the assessment of the immune status of the population. We explored the utility of SARS-CoV-2 virus-like particles (VLPs) as antigens to detect specific humoral immune reactions in an enzyme-linked immun...

  • Article
  • Open Access
7 Citations
5,125 Views
15 Pages

Immunogenicity and Protective Activity of Pigeon Circovirus Recombinant Capsid Protein Virus-Like Particles (PiCV rCap-VLPs) in Pigeons (Columba livia) Experimentally Infected with PiCV

  • Huai-Ying Huang,
  • Benji Brayan I. Silva,
  • Shen-Pang Tsai,
  • Ching-Yi Tsai,
  • Yu-Chang Tyan,
  • Tzu-Che Lin,
  • Ronilo Jose D. Flores and
  • Kuo-Pin Chuang

28 January 2021

Pigeon circovirus (PiCV) is the most recurrent virus diagnosed in pigeons and is among the major causative agents of young pigeon disease syndrome (YPDS). Due to the lack of an established laboratory protocol for PiCV cultivation, development of prop...

  • Review
  • Open Access
37 Citations
8,530 Views
21 Pages

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy

  • Francesca Ruzzi,
  • Maria Sofia Semprini,
  • Laura Scalambra,
  • Arianna Palladini,
  • Stefania Angelicola,
  • Chiara Cappello,
  • Olga Maria Pittino,
  • Patrizia Nanni and
  • Pier-Luigi Lollini

19 August 2023

Cancer vaccines are increasingly being studied as a possible strategy to prevent and treat cancers. While several prophylactic vaccines for virus-caused cancers are approved and efficiently used worldwide, the development of therapeutic cancer vaccin...

  • Article
  • Open Access
15 Citations
3,183 Views
13 Pages

Transdermal Vaccination with the Matrix-2 Protein Virus-like Particle (M2e VLP) Induces Immunity in Mice against Influenza A Virus

  • Kimberly Braz Gomes,
  • Sucheta D’Sa,
  • Grace Lovia Allotey-Babington,
  • Sang-Moo Kang and
  • Martin J. D’Souza

15 November 2021

In this study, our goal was to utilize the extracellular domain matrix-2 protein virus-like particle (M2e VLP) that has been found to be highly conserved amongst all strains of influenza and could serve as a potential vaccine candidate against influe...

  • Article
  • Open Access
9 Citations
4,796 Views
18 Pages

An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line

  • Stefan Hirschberg,
  • Fatemeh Ghazaani,
  • Ghada Ben Amor,
  • Markus Pydde,
  • Alexander Nagel,
  • Saveria Germani,
  • Lara Monica,
  • Anja Schlör,
  • Hannes Bauer and
  • Julian Kamhieh-Milz
  • + 11 authors

9 September 2023

The rapid evolution of new SARS-CoV-2 variants poses a continuing threat to human health. Vaccination has become the primary therapeutic intervention. The goal of the current work was the construction of immunogenic virus-like particles (VLPs). Here,...

  • Review
  • Open Access
5 Citations
3,956 Views
28 Pages

Safe and effective T cell vaccines are needed for the treatment or prevention of cancers as well as infectious agents where vaccines for neutralizing antibodies have performed poorly. Recent research highlights an important role for tissue-resident m...

  • Article
  • Open Access
5 Citations
3,994 Views
18 Pages

23 February 2023

Since the outbreak of the coronavirus disease 2019 (COVID-19), various vaccines have been developed for emergency use. The efficacy of the initial vaccines based on the ancestral strain of severe acute respiratory syndrome coronavirus type 2 (SARS-Co...

  • Review
  • Open Access
7 Citations
9,172 Views
17 Pages

Virus-like Particles (VLPs) as Important Tools for Flavivirus Vaccine Development

  • Leda R. Castilho,
  • Nathalia R. Mattos,
  • Wallace S. Abreu and
  • Melissa L. E. Gutarra

31 October 2022

Flaviviruses, such as dengue, zika, yellow fever, West Nile, and Japanese encephalitis virus, are RNA viruses belonging to the Flaviviridae family (genus Flavivirus). They represent an important global health concern, since most areas of the world ar...

  • Article
  • Open Access
31 Citations
8,637 Views
15 Pages

Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax

  • Gustavo Cabral-Miranda,
  • Matthew D. Heath,
  • Mona O. Mohsen,
  • Ariane C. Gomes,
  • Paul Engeroff,
  • Amy Flaxman,
  • Fabiana M. S. Leoratti,
  • Aadil El-Turabi,
  • Arturo Reyes-Sandoval and
  • Martin F. Bachmann
  • + 1 author

Vaccination is the most effective prophylactic tool against infectious diseases. Despite continued efforts to control malaria, the disease still generally represents a significant unmet medical need. Microcrystalline tyrosine (MCT) is a well describe...

  • Article
  • Open Access
8 Citations
2,860 Views
16 Pages

Towards Autonomous Process Control—Digital Twin for HIV-Gag VLP Production in HEK293 Cells Using a Dynamic Metabolic Model

  • Heribert Helgers,
  • Alina Hengelbrock,
  • Jamila Franca Rosengarten,
  • Jörn Stitz,
  • Axel Schmidt and
  • Jochen Strube

5 October 2022

Despite intensive research over the last three decades, it has not yet been possible to bring an effective vaccine against human immunodeficiency virus (HIV) and the resulting acquired immunodeficiency syndrome (AIDS) to market. Virus-like particles...

  • Article
  • Open Access
2 Citations
2,929 Views
20 Pages

Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes

  • Yongping Yang,
  • Wing-Pui Kong,
  • Cuiping Liu,
  • Tracy J. Ruckwardt,
  • Yaroslav Tsybovsky,
  • Lingshu Wang,
  • Shuishu Wang,
  • Daniel W. Biner,
  • Man Chen and
  • Peter D. Kwong
  • + 13 authors

31 August 2023

New vaccine delivery technologies, such as mRNA, have played a critical role in the rapid and efficient control of SARS-CoV-2, helping to end the COVID-19 pandemic. Enveloped virus-like particles (eVLPs) are often more immunogenic than protein subuni...

  • Review
  • Open Access
15 Citations
6,434 Views
17 Pages

The designer nucleases, including Zinc Finger Nuclease (ZFN), Transcription Activator-Like Effector Nuclease (TALEN), and Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated (CRISPR/Cas), have been widely used for mechanistic...

  • Review
  • Open Access
39 Citations
8,012 Views
18 Pages

8 May 2020

In the midst of the ongoing COVID-19 coronavirus pandemic, influenza virus remains a major threat to public health due to its potential to cause epidemics and pandemics with significant human mortality. Cases of H7N9 human infections emerged in easte...

  • Review
  • Open Access
66 Citations
9,796 Views
20 Pages

Virus-like Particles as Preventive and Therapeutic Cancer Vaccines

  • Anna Lucia Tornesello,
  • Maria Tagliamonte,
  • Franco M. Buonaguro,
  • Maria Lina Tornesello and
  • Luigi Buonaguro

2 February 2022

Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the native virus structure without being infectious. VLPs, similarly to wild type viruses, are able to efficiently target and activate dendritic cells (DCs) triggering...

  • Article
  • Open Access
11 Citations
3,333 Views
11 Pages

19 January 2023

The manufacture and downstream processing of virus-like particles (VLPs) using the baculovirus expression vector system (BEVS) is complicated by the presence of large concentrations of baculovirus particles, which are similar in size and density to V...

  • Review
  • Open Access
65 Citations
15,458 Views
18 Pages

10 April 2021

Virus-like particles (VLPs) are increasingly used for vaccine development and drug delivery. Assembly of VLPs from purified monomers in a chemically defined reaction is advantageous compared to in vivo assembly, because it avoids encapsidation of hos...

  • Article
  • Open Access
12 Citations
4,664 Views
22 Pages

Chimeric RHDV Virus-Like Particles Displaying Foot-and-Mouth Disease Virus Epitopes Elicit Neutralizing Antibodies and Confer Partial Protection in Pigs

  • Giselle Rangel,
  • Juan Bárcena,
  • Noelia Moreno,
  • Carlos P. Mata,
  • José R. Castón,
  • Alí Alejo and
  • Esther Blanco

Currently there is a clear trend towards the establishment of virus-like particles (VLPs) as a powerful tool for vaccine development. VLPs are tunable nanoparticles that can be engineered to be used as platforms for multimeric display of foreign anti...

  • Article
  • Open Access
12 Citations
16,818 Views
11 Pages

Assembly and Characterization of HBc Derived Virus-like Particles with Magnetic Core

  • Jakub Dalibor Rybka,
  • Adam Aron Mieloch,
  • Alicja Plis,
  • Marcin Pyrski,
  • Tomasz Pniewski and
  • Michael Giersig

26 January 2019

Core-virus like particles (VLPs) assembly is a kinetically complex cascade of interactions between viral proteins, nanoparticle’s surface and an ionic environment. Despite many in silico simulations regarding this process, there is still a lack...

  • Article
  • Open Access
2 Citations
2,615 Views
15 Pages

5 February 2025

Enzymes play an essential role in many different industries; however, their operating conditions are limited due to the loss of enzyme activity in the presence of proteases and at temperatures significantly above physiological conditions. One way to...

  • Review
  • Open Access
16 Citations
5,977 Views
12 Pages

RNA Phage VLP-Based Vaccine Platforms

  • David S. Peabody,
  • Julianne Peabody,
  • Steven B. Bradfute and
  • Bryce Chackerian

4 August 2021

Virus-like particles from a variety of RNA bacteriophages have turned out to be useful platforms for delivery of vaccine antigens in a highly immunogenic format. Here we update the current state of development of RNA phage VLPs as platforms for prese...

  • Article
  • Open Access
13 Citations
4,770 Views
17 Pages

Two RSV Platforms for G, F, or G+F Proteins VLPs

  • Binh Ha,
  • Jie E. Yang,
  • Xuemin Chen,
  • Samadhan J. Jadhao,
  • Elizabeth R. Wright and
  • Larry J. Anderson

19 August 2020

Respiratory syncytial virus (RSV) causes substantial lower respiratory tract disease in children and at-risk adults. Though there are no effective anti-viral drugs for acute disease or licensed vaccines for RSV, palivizumab prophylaxis is available f...

  • Feature Paper
  • Article
  • Open Access
20 Citations
4,288 Views
22 Pages

Process Design and Optimization towards Digital Twins for HIV-Gag VLP Production in HEK293 Cells, including Purification

  • Heribert Helgers,
  • Alina Hengelbrock,
  • Axel Schmidt,
  • Jamila Rosengarten,
  • Jörn Stitz and
  • Jochen Strube

21 February 2022

Despite great efforts to develop a vaccine against human immunodeficiency virus (HIV), which causes AIDS if untreated, no approved HIV vaccine is available to date. A promising class of vaccines are virus-like particles (VLPs), which were shown to be...

  • Review
  • Open Access
4 Citations
9,657 Views
21 Pages

Yeast and Virus-like Particles: A Perfect or Imperfect Couple?

  • Sara Brachelente,
  • Alvaro Galli and
  • Tiziana Cervelli

Virus-like particles (VLPs) comprise viral structural proteins that self-assemble to form a particle similar to the native virus capsid. Since their discovery, they have been employed mainly as vaccines to prevent viral infection because they can eli...

  • Article
  • Open Access
11 Citations
3,317 Views
15 Pages

Immunogenicity of Multi-Target Chimeric RHDV Virus-Like Particles Delivering Foreign B-Cell Epitopes

  • María Zamora-Ceballos,
  • Noelia Moreno,
  • David Gil-Cantero,
  • José R. Castón,
  • Esther Blanco and
  • Juan Bárcena

2 February 2022

The rabbit hemorrhagic disease virus (RHDV) vaccine platform is a nanoparticle composed of 180 copies of the viral capsid protein, VP60, self-assembled into virus-like particles (VLPs). RHDV VLPs are able to accept the simultaneous incorporation of t...

  • Review
  • Open Access
98 Citations
10,851 Views
24 Pages

Virus-like Particle Vaccines and Platforms for Vaccine Development

  • Milad Kheirvari,
  • Hong Liu and
  • Ebenezer Tumban

2 May 2023

Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use of VLP-based vaccines to protect against three infectious agents—hepatitis B virus, human papillomavirus, and hepatitis E virus—has been approv...

  • Feature Paper
  • Review
  • Open Access
4 Citations
3,464 Views
23 Pages

Virus-like particles (VLPs) exhibit such unique colloidal and structural properties that make them ideal candidates for various bio-nanotechnology applications, among which mucosal vaccination is particularly promising. However, since mucosal surface...

  • Article
  • Open Access
12 Citations
5,304 Views
36 Pages

Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env

  • Christopher A. Gonelli,
  • Hannah A. D. King,
  • Charlene Mackenzie,
  • Secondo Sonza,
  • Rob J. Center and
  • Damian F. J. Purcell

10 March 2021

An optimal prophylactic vaccine to prevent human immunodeficiency virus (HIV-1) transmission should elicit protective antibody responses against the HIV-1 envelope glycoprotein (Env). Replication-incompetent HIV-1 virus-like particles (VLPs) offer th...

  • Article
  • Open Access
16 Citations
4,423 Views
16 Pages

Baculovirus-Free SARS-CoV-2 Virus-like Particle Production in Insect Cells for Rapid Neutralization Assessment

  • Marcel Jaron,
  • Michael Lehky,
  • Marta Zarà,
  • Chris Nicole Zaydowicz,
  • Aidin Lak,
  • Rico Ballmann,
  • Philip Alexander Heine,
  • Esther Veronika Wenzel,
  • Kai-Thomas Schneider and
  • Maren Schubert
  • + 6 authors

20 September 2022

Virus-like particles (VLPs) resemble authentic virus while not containing any genomic information. Here, we present a fast and powerful method for the production of SARS-CoV-2 VLP in insect cells and the application of these VLPs to evaluate the inhi...

  • Article
  • Open Access
12 Citations
4,941 Views
13 Pages

A Virus-Like Particle-Based Vaccine Candidate against the Tick-Borne Powassan Virus Induces Neutralizing Antibodies in a Mouse Model

  • Velasco Cimica,
  • Sahar Saleem,
  • Emily Matuczinski,
  • Debra Adams-Fish,
  • Conor McMahon,
  • Sujatha Rashid and
  • Timothy T. Stedman

Powassan virus (POWV) is a tick-borne flavivirus circulating in North America and the Russian Far East that can cause severe neuroinvasive diseases, including encephalitis, meningitis, and meningoencephalitis. The reported neuroinvasive case fatality...

  • Review
  • Open Access
1 Citations
3,556 Views
14 Pages

26 June 2023

Most acute gastroenteritis (AGE) outbreaks and sporadic cases in developing countries are attributable to infection by human norovirus (HuNoV), the enteric virus mainly transmitted via fecal-contaminated water. However, it has been challenging to stu...

  • Article
  • Open Access
20 Citations
6,034 Views
14 Pages

Efficient Production of Chimeric Hepatitis B Virus-Like Particles Bearing an Epitope of Hepatitis E Virus Capsid by Transient Expression in Nicotiana benthamiana

  • Gergana Zahmanova,
  • Milena Mazalovska,
  • Katerina Takova,
  • Valentina Toneva,
  • Ivan Minkov,
  • Hadrien Peyret and
  • George Lomonossoff

17 January 2021

The core antigen of hepatitis B virus (HBcAg) is capable of self-assembly into virus-like particles (VLPs) when expressed in a number of heterologous systems. Such VLPs are potential carriers of foreign antigenic sequences for vaccine design. In this...

  • Article
  • Open Access
2 Citations
2,213 Views
18 Pages

Foot-and-Mouth Disease Virus-like Particles Produced in E. coli as Potential Antigens for a Novel Vaccine

  • Sang-Cheol Yu,
  • In-Kyu Lee,
  • Hyun-Seok Kong,
  • Sung-Ho Shin,
  • Sung-Yoon Hwang,
  • Yu-Jin Ahn,
  • Jong-Hyeon Park,
  • Bong-Yoon Kim and
  • Young-Cheon Song

Foot-and-mouth disease virus (FMDV) continues to pose a significant threat to livestock health and the global agricultural economy, particularly in endemic regions of Asia, Africa, and the Middle East. Current vaccines based on chemically inactivated...

  • Article
  • Open Access
13 Citations
4,179 Views
11 Pages

Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus

  • Haiyan Sun,
  • Dhiraj Acharya,
  • Amber M. Paul,
  • Huafang Lai,
  • Junyun He,
  • Fengwei Bai and
  • Qiang Chen

17 January 2023

West Nile virus (WNV) causes annual outbreaks globally and is the leading cause of mosquito-borne disease in Unite States. In the absence of licensed therapeutics, there is an urgent need to develop effective and safe human vaccines against WNV. One...

  • Article
  • Open Access
1 Citations
3,712 Views
23 Pages

24 May 2024

Respiratory syncytial virus (RSV) is a major cause of severe respiratory tract disease worldwide, and a pediatric vaccine is not available. We generated a filamentous RSV-based virus-like particle (VLP) that presents the central conserved region of t...

  • Article
  • Open Access
17 Citations
7,037 Views
13 Pages

Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine

  • Minna M. Hankaniemi,
  • Mo A. Baikoghli,
  • Virginia M. Stone,
  • Li Xing,
  • Outi Väätäinen,
  • Saana Soppela,
  • Amirbabak Sioofy-Khojine,
  • Niila V. V. Saarinen,
  • Tingwei Ou and
  • Olli H. Laitinen
  • + 5 authors

Coxsackievirus B (CVB) enteroviruses are common pathogens that can cause acute and chronic myocarditis, dilated cardiomyopathy, aseptic meningitis, and they are hypothesized to be a causal factor in type 1 diabetes. The licensed enterovirus vaccines...

  • Article
  • Open Access
6 Citations
3,092 Views
14 Pages

Transdermal Immunization with Microparticulate RSV-F Virus-like Particles Elicits Robust Immunity

  • Sucheta D’Sa,
  • Kimberly Braz Gomes,
  • Grace Lovia Allotey-Babington,
  • Cemil Boyoglu,
  • Sang-Moo Kang and
  • Martin J. D’Souza

10 April 2022

No approved vaccines against respiratory syncytial virus (RSV) infections exist to date, due to challenges arising during vaccine development. There is an unmet need to explore novel approaches and a universal strategy to prevent RSV infections. Prev...

  • Review
  • Open Access
9 Citations
5,683 Views
14 Pages

An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines

  • Doddy Irawan Setyo Utomo,
  • Hamizah Suhaimi,
  • Nor Azila Muhammad Azami,
  • Fazren Azmi,
  • Mohd Cairul Iqbal Mohd Amin and
  • Jian Xu

20 September 2023

Recently, a great effort has been devoted to studying attenuated and subunit vaccine development against SARS-CoV-2 since its outbreak in December 2019. It is known that diverse virus-like particles (VLPs) are extensively employed as carriers to disp...

  • Review
  • Open Access
35 Citations
8,196 Views
23 Pages

4 August 2015

The HPV viral lifecycle is tightly linked to the host cell differentiation, causing difficulty in growing virions in culture. A system that bypasses the need for differentiating epithelium has allowed for generation of recombinant particles, such as...

  • Review
  • Open Access
37 Citations
13,415 Views
23 Pages

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery

  • Vartika Srivastava,
  • Kripa N. Nand,
  • Aijaz Ahmad and
  • Ravinder Kumar

18 February 2023

Virus-like particles (VLPs) are empty, nanoscale structures morphologically resembling viruses. Internal cavity, noninfectious, and particulate nature with a high density of repeating epitopes, make them an ideal platform for vaccine development and...

  • Article
  • Open Access
21 Citations
4,536 Views
13 Pages

17 January 2021

In this study, we developed a hepatitis B core antigen (HBcAg)-based virus-like particle (VLP) that displays the West Nile virus (WNV) Envelope protein domain III (wDIII) as a vaccine candidate for WNV. The HBcAg-wDIII fusion protein was quickly prod...

  • Article
  • Open Access
19 Citations
4,637 Views
14 Pages

Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses

  • Katrin Campbell,
  • Vivienne L. Young,
  • Braeden C. Donaldson,
  • Matthew J. Woodall,
  • Nicholas J. Shields,
  • Greg F. Walker,
  • Vernon K. Ward and
  • Sarah L. Young

Breast cancer (BC) is the most frequently diagnosed cancer in women, with many patients experiencing recurrence following treatment. Antigens delivered on virus-like particles (VLPs) induce a targeted immune response and here we investigated whether...

  • Article
  • Open Access
7 Citations
3,148 Views
13 Pages

Immunogenicity and Antigenicity of Rabbit Hepatitis E Virus-Like Particles Produced by Recombinant Baculoviruses

  • Huimin Bai,
  • Michiyo Kataoka,
  • Yasushi Ami,
  • Yuriko Suzaki,
  • Naokazu Takeda,
  • Masamichi Muramatsu and
  • Tian-Cheng Li

9 August 2021

Rabbit hepatitis E virus (HEV) is a novel HEV belonging to genotype 3 (HEV-3) in the Orthohepevirus A species of the genus Hepevirus, family Hepeviridae. Rabbit HEV was originally isolated from rabbits and found to cause zoonotic infection. Although...

  • Article
  • Open Access
15 Citations
6,056 Views
19 Pages

A HER2-Displaying Virus-Like Particle Vaccine Protects from Challenge with Mammary Carcinoma Cells in a Mouse Model

  • Lisa Nika,
  • Sara Cuadrado-Castano,
  • Guha Asthagiri Arunkumar,
  • Clemens Grünwald-Gruber,
  • Meagan McMahon,
  • Krisztina Koczka,
  • Adolfo García-Sastre,
  • Florian Krammer and
  • Reingard Grabherr

Human epidermal growth factor receptor-2 (HER2) is upregulated in 20% to 30% of breast cancers and is a marker of a poor outcome. Due to the development of resistance to passive immunotherapy with Trastuzumab, active anti-HER2 vaccination strategies...

  • Article
  • Open Access
8 Citations
3,805 Views
22 Pages

Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2

  • Matthew D. Resch,
  • Ke Wen,
  • Ryan Mazboudi,
  • Hannah Mulhall Maasz,
  • Mirjana Persaud,
  • Kaitlyn Garvey,
  • Leslie Gallardo,
  • Paul Gottlieb,
  • Aleksandra Alimova and
  • Jose M. Galarza
  • + 3 authors

24 November 2022

Virus-like particles (VLPs) offer great potential as a safe and effective vaccine platform against SARS-CoV-2, the causative agent of COVID-19. Here, we show that SARS-CoV-2 VLPs can be generated by expression of the four viral structural proteins in...

  • Article
  • Open Access
16 Citations
4,734 Views
15 Pages

Bovine viral diarrhea virus (BVDV) is an important animal pathogen that affects cattle. Infections caused by the virus have resulted in substantial economic losses and outbreaks of BVDV are reported globally. Virus-like particles (VLPs) are promising...

  • Article
  • Open Access
14 Citations
3,411 Views
16 Pages

A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines

  • Louise Goksøyr,
  • Magdalena Skrzypczak,
  • Maureen Sampson,
  • Morten A. Nielsen,
  • Ali Salanti,
  • Thor G. Theander,
  • Alan T. Remaley,
  • Willem A. De Jongh and
  • Adam F. Sander

20 December 2022

Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the format...

  • Review
  • Open Access
6 Citations
3,910 Views
23 Pages

The Role of Plant Virus-like Particles in Advanced Drug Delivery and Vaccine Development: Structural Attributes and Application Potential

  • Esperanza Peralta-Cuevas,
  • Igor Garcia-Atutxa,
  • Alejandro Huerta-Saquero and
  • Francisca Villanueva-Flores

23 January 2025

Plant virus-like particles (pVLPs) present distinct research advantages, including cost-effective production and scalability through plant-based systems, making them a promising yet underutilized alternative to traditional VLPs. Human exposure to pla...

of 11